GlassScriptPhysician profile
Mikhail Vaysberg
NPI 1083639561
$929.78
in general payments reported to CMS, 2019-2025
21 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Plastic Surgery Within The Head & Neck provider received nationally (typical 2025 total: $238).
See the full distribution for Plastic Surgery within the Head & Neck
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $22.68 · 2021: $115 · 2022: $219 · 2023: $43.45 · 2024: $63.01 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $112.04 | 2022 | |
| Merck Sharp & Dohme LLC | $100.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $98.39 | 2021-2025 | |
| Janssen Biotech, INC. | $70.84 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $58.49 | 2022-2025 | Dupixent |
| Acclarent, INC | $58.19 | 2019 | |
| Incyte Corporation | $56.77 | 2021-2023 | Opzelura |
| Stryker Corporation | $54.91 | 2019 | |
| Genzyme Corporation | $39.99 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $35.44 | 2025 | Acthar |
| Leo Pharma INC. | $35.41 | 2019-2022 | |
| Genentech USA, INC. | $34.19 | 2021 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $29.88 | 2024 | |
| Amgen INC. | $24.96 | 2019 | |
| Celgene Corporation | $21.37 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.99 | 2021 | |
| Aerin Medical INC. | $19.62 | 2025 | |
| Mayne Pharma Commercial LLC | $15.61 | 2019 | |
| Smith+Nephew, INC. | $15.31 | 2022 | |
| Abbvie INC. | $14.99 | 2019 | |
| Biofrontera INC. | $12.39 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Vaysberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.